Current Research in Drug Discovery

Associate Editors

  • Hongtao Lu
    Vice President & Chief Scientific Officer, Zai Laboratory Inc.
    Expertise: Target identification and validation, biomarker discovery, cell-based assay, phenotypic screening, T cell subset differentiation, inflammatory diseases and neurodegenrative diseases.
  • Jan Eickhoff
    Dortmund GmbH, Head of Assay Development and Screening, Hit Discovery Constance GmbH, Managing Director
    Expertise: Chemical Biology, Medicinal Chemistry, Biochemistry
  • Levente Karpati
    Semmelweis University, Faculty of Pharmacology

Editorial Board Members

  • Andy Zayenga
    Managing Director, SmarterLab - Laboratory Automation Consulting
    United States
    Expertise: Laboratory automation, compound management, high throughput screening, drug discovery, assay development, screening technologies, liquid handling, microfluidics, biobanking, biorepository automation, biostorage and environmental repository operation, business development, process analysis and recommendation, system integration and implementation, project management.
  • David Tattersall
    Director Parkinson’s Disease Group Neurodegeneration DPU, GlaxoSmithKline.
    United Kingdom
    Expertise: Target and lead identification and validation, biomarkers discovery, biobanking, phenotypic screening
  • David John Hayes
    United States
    Expertise: Drug discovery, assay development, enzymology, HTS, biomarker discovery, immuno-assay, multiplex technologies, label-free technologies, protein biochemistry, toxicity, cell based assays, kinases, proteases
  • Davide Gianni
    Team Leader
    Innovative Medicines and Early Development
    Discovery Sciences - Cellular Assay Development
    United Kingdom
    Expertise: Target and lead identification and validation, biomarkers discovery, cell based assay, assay development and validation
  • Gael Hédou
    Neurosciences Centre of Excellence for Drug Discovery
    United Kingdom
    Expertise: target and lead identification and validation, biomarkers discovery, ADME, pharmacology, in vivo pharmacology, preclinical experimental design, lean drug discovery and development, compoound selection and optimization
  • Jad Abdallah
    Lebanese American University
    Expertise: Biochemistry, Genetics and Molecular Biology Immunology and Microbiology Medicine Multidisciplinary Neuroscience Psychology
  • Jonathan Wingfield
    University of Wales
    United Kingdom
    Expertise: Assay development, laboratory automation, high content imaging, mass spectrometry, LIMS.
  • Leonardo J. Solmesky
    Weizmann Institute of Science
    Expertise: Laboratory automation, assay development and validation, high content analysis, biomarkers discovery, cell based assay, phenotypic screening, facility management, and personalized drug discovery
  • Luigi Piero Stasi
    Expertise: Medicinal chemistry, lead identification, ADME, CNS.
  • Luigi Formisano
    Unisannio Univ, Benevento
    Expertise: Cell Based Assay, Cell Culture, Miscroscopy, Flow Cytometry, Cell Biology, Pharmacology, Toxicology, Molecular Biology, Protein Biochemistry, Protein-Protein Interaction, Epigenetic and Neurodegenerative Diseases
  • Masamitsu Kanada
    Michigan State University
    United States
    Expertise: Cell Biology, Cancer Biology, Extracellular Vesicle Biology, Gene Therapy, Drug Delivery, In Vivo Small Animal Imaging
  • Matt Boeckeler
    Automation & Research Technologies Team Chair, AstraZeneca
    United States
    Expertise: Compound Management, high throughput screening, biobanking, assay development, laboratory automation development and implementation, laboratory information systems, value chain optimization and operations, change management leadership, cross-functional team building, process improvement
  • Ming Qiang Zhang
    Vice President & Head Research & Development China, Amgen Inc.
    Expertise: Medicinal chemistry of antiviral, anticancer, anti-inflammatory/anti-allergic, CNS, agents, Heterocyclic, neucleside/tides, carbohydrate, national products / macrocycles, supramolecular / host-guest chemistry, Biomarker, patient stratification, clinical trials and regulatory
  • Narendra Pamidi
    School of Medicine, Monash University Malaysia
    Expertise: Medicine Biochemistry, Genetics and Molecular Biology Neuroscience
  • Paul Andrews
    Stem Cell Solutions Ltd
    Expertise: Screening technologies, target identification and validation, laboratory automation, assay development and validation, high content analysis, data mining, biomarkers discovery, biobanking, cell based assays, use of stem cells in drug discovery, iPS-disease modelling, phenotypic screening
  • Pratima Srivastava
    Associate Director Biology, GVK Biosciences
    Expertise: Drug metabolism and pharmacokinetics, pharmacogenomics, pharmacology, toxicology, molecular biology.
  • Qiyue Hu
    Associate Director, Shanghai Hengrui Pharmaceutical Co.
    Expertise: Computational chemistry, cheminformatics, structure-based drug discovery, ligand-based drug design, bioinformatics, virtual Screening, hit-to-lead, medicinal chemistry, antibody modeling, protein design.
  • Rathnam Chaguturu
    Founder and CEO, iDDPartners
    United States
    Expertise: Target identification-validation, high throughput screening, pharmacology, PK/PD, ADME.
  • Raymond Zhao
    Neuroscience Therapeutic Area Unit, GlaxoSmithKline
    Expertise: Screening technologies, target and lead identification and validation, laboratory automation, assay development and validation, biomarkers discovery, ADME, BioMEMS, Phenotypic screening.
  • Rusliza Basir
    Universiti Putra Malaysia
    Expertise: Medicine Chemistry Immunology and Microbiology Biochemistry, Genetics and Molecular Biology Pharmacology, Toxicology and Pharmaceutics Chemical Engineering Computer Science
  • Sanjeev Saxena
    Senior Research Scientist, Orchid Chemicals & Pharmaceuticals Ltd
    Expertise: Target and lead identification and validation, in vitro and in vivo pharmacology, disease models, biomarker discovery.
  • Sheraz Gul
    University of California
    United States
    Expertise: Assay development, high throughput screening, enzymology, biochemical assays, cell-based assays, drug discovery, high content analysis, data mining, biomarkers discovery, ADME, microfluidics, sample management, cell based assay, 3D cell culture.
  • Timothy Dawes
    Sr. Scientific Manager, Genentech Inc
    United States
    Expertise: Screening technologies, laboratory automation, high throughput screening, assay development and validation, data mining, microfluidics, sample management, cell based assays and biobanking.
  • Tiziana Adage
    BIT Pharma GmbH
    Expertise: Non-clinical and early clinical pharmacology in the areas of inflammatory and autoimmune diseases, diabetes type 1 and type 2, obesity, neurodegeneration, neuropsychopharmacology, oncology, respiratory diseases and in vivo phenotyping screening. In vitro pharmacology, assay development and validation, bioanalytics, biomarker discovery and translational medicine.
  • Tsutomu Kamiyama
    General Manager of Discovery Screening, Mitsubishi Tanabe Pharma Corporation
    Expertise: small molecule drug discovery, high throughput screening, screening technologies, lead identification and validation, laboratory automation, ADMET-HTS, sample management and natural products screening
  • Tülay Bakirel
    Istanbul University
    Expertise: Pharmacology, Toxicology, Pharmacokinetics, Medical Plants, Antineoplastic drugs

Past Editors

  • Giancarlo Basile
    Editor in Chief
    Jan, 2014 - Jun, 2015